Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

Overview of attention for article published in Frontiers in oncology, July 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,555 followers.

New Research: Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation https://t.co/2e2vWviIeA #FrontiersIn #Oncology

24 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.